Akira E. Takemori

Akira E. Takemori's AcademicInfluence.com Rankings

Akira E. Takemori

Chemistry

#2501

World Rank

#3419

Historical Rank

Organic Chemistry

#372

World Rank

#440

Historical Rank

chemistry Degrees

Download Badge

Chemistry

Akira E. Takemori's Degrees

PhD Chemistry University of California, Berkeley
Bachelors Chemistry Stanford University

Why Is Akira E. Takemori Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Akira E. Takemori's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Naltrindole, a highly selective and potent non-peptide δ opioid receptor antagonist (1988) (515)
Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. (1987) (497)
Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. (1988) (410)
Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. (1991) (405)
Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. (1991) (345)
Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine. (1982) (294)
Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists. (1988) (291)
Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5'-isothiocyanate: evidence for delta receptor subtypes. (1991) (278)
A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities. (1980) (274)
Design of peptidomimetic delta opioid receptor antagonists using the message-address concept. (1990) (233)
The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone. (1981) (220)
Differential effects of leucine and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence. (1979) (198)
Kappa receptor regulation of dopamine release from striatum and cortex of rats and guinea pigs. (1988) (178)
A highly selective δ1-opioid receptor antagonist : 7-benzylidenenaltrexone (1992) (158)
Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice. (1983) (156)
Enhanced oxidation of α-glycerophosphate by mitochondria of thyroid-fed rats. (1959) (146)
Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. (1988) (144)
Spinal opioid delta antinociception in the mouse: mediation by a 5'-NTII-sensitive delta receptor subtype. (1992) (128)
Effect of antagonists selective for mu, delta and kappa opioid receptors on the reinforcing effects of heroin in rats. (1993) (127)
Selective naltrexone-derived opioid receptor antagonists. (1992) (125)
Binaltorphimine-related bivalent ligands and their kappa opioid receptor antagonist selectivity. (1988) (124)
Pharmacological profiles of β-funaltrexamine (β-FNA) and β-chlornaltrexamine (β-CNA) on the mouse vas deferens preparation (1982) (117)
Modulation of mu-mediated antinociception in the mouse involves opioid delta-2 receptors. (1992) (117)
The type of analgesic-receptor interaction involved in certain analgesic assays. (1971) (112)
The increased efficacy of narcotic antagonists induced by various narcotic analgesics. (1974) (109)
Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine. Evidence for bridging between proximal recognition sites. (1982) (107)
Bimorphinans as highly selective, potent kappa opioid receptor antagonists. (1987) (99)
Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in beta-funaltrexamine-treated mice. (1987) (99)
Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties. (1979) (98)
Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole. (1991) (93)
Affinity labels for opioid receptors. (1985) (90)
Effects of (-)-N6-(R-phenylisopropyl)-adenosine (PIA) and caffeine on nociception and morphine-induced analgesia, tolerance and dependence in mice. (1985) (86)
The effect of biogenic amine modifiers on morphine analgesia and its antagonism by naloxone. (1976) (86)
Involvement of delta 2 opioid receptors in the development of morphine dependence in mice. (1993) (86)
Antagonism of morphine-induced analgesia, tolerance and dependence by alpha-melanocyte-stimulating hormone. (1984) (85)
Antagonism by naloxone of narcotic-induced respiratory depression and analgesia. (1978) (84)
Relative involvement of receptor subtypes in opioid-induced inhibition of gastrointestinal transit in mice. (1983) (83)
Quantitative studies on the antagonism by naloxone of some narcotic and narcotic‐antagonist analgesics (1970) (80)
Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors. (1986) (78)
Suppression by dynorphin A-(1-13) of the expression of opiate withdrawal and tolerance in mice. (1992) (77)
7-Benzylidenenaltrexone (BNTX): A selective δ1 opioid receptor antagonist in the mouse spinal cord (1993) (76)
Role of spinal mu opioid receptors in the development of morphine tolerance and dependence. (1984) (72)
Agonist and antagonist activities of ligands derived from naltrexone and oxymorphone. (1992) (72)
Suppression by dynorphin A and [des-Tyr1]dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice. (1993) (71)
Opioid agonist and antagonist bivalent ligands as receptor probes. (1982) (70)
Naltrindole 5'-isothiocyanate: a nonequilibrium, highly selective delta opioid receptor antagonist. (1990) (68)
Studies on the relationship between 5-hydroxytryptamine turnover in brain and tolerance and physical dependence in mice. (1971) (67)
The effect of dopaminergic stimulation and blockade on the nociceptive and antinociceptive responses of mice. (1975) (64)
Serotonergic involvement in the antinociceptive action of and the development of tolerance to the kappa-opioid receptor agonist, U-50, 488H. (1989) (63)
Inhibition by naloxone of tolerance and dependence in mice treated acutely and chronically with morphine. (1977) (62)
The potentiation of spinal analgesia by leucine enkephalin. (1980) (61)
Further studies on the alteration of analgesic receptor-antagonist interaction induced by morphine. (1974) (61)
Alteration of analgesic receptor-antagonist interaction induced by morphine. (1973) (61)
Mediation of swim-stress antinociception by the opioid delta 2 receptor in the mouse. (1992) (61)
A selective delta 1 opioid receptor agonist derived from oxymorphone. Evidence for separate recognition sites for delta 1 opioid receptor agonists and antagonists. (1993) (61)
Quantitative studies of the antagonism of morphine by nalorphine and naloxone. (1969) (60)
Improved assays for the assessment of ϰ- and δ-properties of opioid ligands (1982) (59)
Comparative antagonism by naltrexone and naloxone of μ, κ, and δ agonists☆ (1984) (59)
Metabolic N- and O-demethylation of morphine- and morphinan-type analgesics. (1958) (57)
Spinal antagonism of tolerance and dependence induced by systemically administered morphine. (1983) (54)
The role of dopamine and norepinephrine in the naloxone-induced abstinence of morphine-dependent mice. (1973) (54)
Effect of fluoxetine hydrochloride (Lilly 110140), a specific inhibitor of serotonin uptake, on morphine analgesia and the development of tolerance. (1977) (54)
Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors. (1985) (53)
Interaction of [D-Pen2,D-Pen5]enkephalin and [D-Ala2,Glu4]deltorphin with delta-opioid receptor subtypes in vivo. (1994) (53)
6.beta.-[N,N-Bis(2-chloroethyl)amino]-17-(cyclopropylmethyl)-4,5.alpha.-epoxy-3,14-dihydroxymorphinan (chloranaltrexamine), a potent opioid receptor alkylating agent with ultralong narcotic antagonist activity (1978) (52)
Selective kappa antagonist properties of nor-binaltorphimine in the rat MES seizure model. (1989) (52)
The μ, κ and δ properties of various opioid agonists☆ (1986) (49)
kappa Opioid receptor selective affinity labels: electrophilic benzeneacetamides as kappa-selective opioid antagonists. (1994) (49)
Biochemistry of drug dependence. (1974) (48)
A further characterization of the differential effects of leucine enkephalin, methionine enkephalin and their analogs on morphine-induced analgesia. (1979) (46)
An ultrasensitive method for the determination of morphine and its application in experiments in vitro and in vivo. (1968) (46)
Enkephalin antinociception in mice is mediated by δ1- and δ2-opioid receptors in the brain and spinal cord, respectively (1993) (45)
Chloroxymorphamine, and opioid receptor site-directed alkylating agent having narcotic agonist activity. (1979) (45)
Mediation of nitrous oxide analgesia in mice by spinal and supraspinal κ-opioid receptors (1990) (45)
3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity. (1993) (44)
Antagonism by chlornaltrexamine of some effects of Δ9-tetrahydrocannabinol in rats (1981) (43)
Studies on the quantitative antagonism of analgesics by naloxone and diprenorphine. (1972) (43)
Different receptor sites mediate opioid agonism and antagonism. (1983) (43)
κ-Selective Opiate Antagonist Nor-Binaltorphimine Improves Outcome After Traumatic Spinal Cord Injury in Rats (1987) (43)
Changes in adenosine receptor sensitivity in morphine-tolerant and -dependent mice. (1986) (42)
Cross-tolerance studies between caffeine and (-)-N6-(phenylisopropyl)-adenosine (PIA) in mice. (1986) (42)
Cross-tolerance studies in the spinal cord of beta-FNA-treated mice provides further evidence for delta opioid receptor subtypes. (1991) (42)
The effect of diazepam on the metabolism of methadone by the liver of methadone-dependent rats. (1974) (42)
delta-Opioid receptor binding in mouse brain: evidence for heterogeneous binding sites. (1992) (41)
Studies on the uptake of morphine by the choroid plexus in vitro. (1966) (40)
Alterations in the antagonism by naloxone of morphine-induced respiratory depression and analgesia after morphine pretreatment. (1978) (40)
Effects of β-funaltrexamine (β-FNA) on morphine dependence in rats and monkeys (1986) (39)
Characteristics of μ and δ opioid binding sites in striatal slices of morphine-tolerant and -dependent mice (1991) (38)
Opioid receptor binding characteristics of the non-equilibrium μ antagonist, β-funaltrexamine (β-FNA)☆ (1985) (38)
Suppression by nor-binaltorphimine of kappa opioid-mediated diuresis in rats. (1988) (38)
Stereochemical studies on medicinal agents. 23. Synthesis and biological evaluation of 6-amino derivatives of naloxone and naltrexone. (1977) (37)
Neurochemical bases for narcotic tolerance and dependence. (1975) (37)
Differential effects on morphine analgesia and naloxone antagonism by biogenic amine modifiers. (1975) (36)
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety. (1994) (36)
Involvement of delta 2 opioid receptors in acute dependence on morphine in mice. (1993) (35)
TENA, a selective kappa opioid receptor antagonist. (1985) (35)
Modulation of morphine antinociception by swim-stress in the mouse: involvement of supraspinal opioid delta-2 receptors. (1993) (34)
Only one pharmacophore is required for the kappa opioid antagonist selectivity of norbinaltorphimine. (1988) (34)
Increased sensitivity to dopamine agonists following a single dose of morphine or levorphanol in mice. (1985) (33)
Role of the spacer in conferring kappa opioid receptor selectivity to bivalent ligands related to norbinaltorphimine. (1991) (33)
Cold water swim stress- and delta-2 opioid-induced analgesia are modulated by spinal gamma-aminobutyric acidA receptors. (1995) (32)
Stimulation by corticotropin-releasing factor of the release of immunoreactive dynorphin A from mouse spinal cords in vitro. (1992) (32)
Pharmacological studies with an alkylating narcotic agonist, chloroxymorphamine, and antagonist, chlornaltrexamine. (1980) (32)
Delta opioid antagonist activity and binding studies of regioisomeric isothiocyanate derivatives of naltrindole: evidence for delta receptor subtypes. (1992) (31)
Chronically administered morphine increases dopamine receptor sensitivity in mice. (1986) (31)
Determination of the relative involvement of mu-opioid receptors in opioid-induced depression of respiratory rate by use of beta-funaltrexamine. (1983) (31)
PHARMACOLOGIC FACTORS WHICH ALTER THE ACTION OF NARCOTIC ANALGESICS AND ANTAGONISTS * (1976) (30)
Isobolographic analysis of analgesic interactions between intrathecally and intracerebroventricularly administered fentanyl, morphine and D-Ala2-D-Leu5-enkephalin in morphine-tolerant and nontolerant mice. (1991) (30)
The effect of repeated administration of levorphan, dextrophan and morphine on the capacity of rat liver preparations to demethylate morphine- and morphinan-type analgesics. (1959) (30)
Studies on the narcotic receptor in the guinea-pig ileum. (1976) (30)
A highly selective delta 1-opioid receptor antagonist: 7-benzylidenenaltrexone. (1992) (30)
Studies on cellular adaptation to morphine and its reversal by nalorphine in cerebral cortical slices of rats. (1962) (28)
Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different mu receptor subtypes in different tissues. (1984) (28)
Comparative antagonism by naltrexone and naloxone of mu, kappa, and delta agonists. (1984) (28)
Supraspinal delta receptor subtype activity of heroin and 6-monoacetylmorphine in Swiss Webster mice. (1994) (28)
Modulation of acute morphine tolerance by corticotropin-releasing factor and dynorphin A in the mouse spinal cord. (1992) (28)
Indirect involvement of delta opioid receptors in cholecystokinin octapeptide-induced analgesia in mice. (1989) (28)
7-Benzylidenenaltrexone (BNTX): a selective delta 1 opioid receptor antagonist in the mouse spinal cord. (1993) (26)
Structure-activity relationship of N17'-substituted norbinaltorphimine congeners. Role of the N17' basic group in the interaction with a putative address subsite on the kappa opioid receptor. (1994) (26)
Enzymic studies on morphine glucronide synthesis in acutely and chronically morphinized rats. (1960) (26)
Evidence for a single functional opioid delta receptor subtype in the mouse isolated vas deferens. (1993) (26)
Selective opioid antagonist effects on opioid-induced inhibition of release of norepinephrine in guinea pig cortex (1989) (25)
Synthesis and opioid antagonist potencies of naltrexamine bivalent ligands with conformationally restricted spacers. (1986) (25)
Involvement of spinal kappa opioid receptors in the antagonistic effect of dynorphins on morphine antinociception. (1991) (24)
Pulsed laser deposition of BaFe2(As,P)2 superconducting thin films with high critical current density (2012) (24)
The effect of dopaminergic modifiers on morphine-induced analgesia and respiratory depression. (1979) (24)
Arylacetamide-derived fluorescent probes: synthesis, biological evaluation, and direct fluorescent labeling of kappa opioid receptors in mouse microglial cells. (1996) (24)
Lack of involvement of delta-1 opioid receptors in the development of physical dependence on morphine in mice. (1994) (24)
A remarkable change of opioid receptor selectivity on the attachment of a peptidomimetic kappa address element to the delta antagonist, natrindole: 5'-[N2-alkylamidino)methyl]naltrindole derivatives as a novel class of kappa opioid receptor antagonists. (1993) (24)
Involvement of spinal kappa opioid receptors in the antinociception produced by intrathecally administered corticotropin-releasing factor in mice. (1990) (24)
2-(3,4-Dichlorophenyl)-N-methyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl]acetamide: an opioid receptor affinity label that produces selective and long-lasting kappa antagonism in mice. (1994) (23)
Synthesis and kappa-opioid antagonist selectivity of a norbinaltorphimine congener. Identification of the address moiety required for kappa-antagonist activity. (1993) (23)
Absorption rates of various substances administered intramuscularly. (1971) (23)
Improved method for morphine extraction from biological samples. (1979) (22)
Importance of C-6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labels. (1983) (22)
N-benzylnaltrindoles as long-acting delta-opioid receptor antagonists. (1994) (22)
Evolution of the phase diagram of LaFeP 1 − x As x O 1 − y F y ( y = 0 – 0.1 ) (2014) (20)
New gas chromatographic method for the analysis of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in the brain. (1971) (20)
Modification of the development of acute opiate tolerance by increased dopamine receptor sensitivity. (1987) (20)
Further studies on the enhanced affinity of opioid receptors for naloxone in morphine-dependent mice. (1979) (20)
Cellular Adaptation to Morphine in Rats (1961) (19)
Opioid agonist and antagonist activities of morphindoles related to naltrindole. (1992) (19)
Receptors for opioid peptides in the guinea-pig ileum. (1985) (19)
Opioid agonist and antagonist activities of peripherally selective derivatives of naltrexamine and oxymorphamine. (1989) (19)
Determination of pharmacological constants: use of narcotic antagonists to characterize analgesic receptors. (1973) (19)
Hybrid bivalent ligands with opiate and enkephalin pharmacophores. (1987) (18)
Attenuation of the antinociceptive action of the selective kappa-opioid receptor agonist, U-50,488H by ICS-205-930. (1990) (18)
Antagonism of morphine antinociception by intrathecally administered corticotropin-releasing factor in mice. (1991) (18)
Facilitation of morphine-induced tolerance and physical dependence by prolyl-leucyl-glycinamide. (1981) (18)
Enkephalin antinociception in mice is mediated by delta 1- and delta 2-opioid receptors in the brain and spinal cord, respectively. (1993) (17)
Maintenance of morphine dependence by naloxone in acutely dependent mice. (1990) (17)
Studies on glucuronide synthesis in rats chronically treated with morphine and phenol. (1962) (17)
Release by U-50,488H of [3H]serotonin from brain slices and spinal cord synaptosomes of U-50,488H-tolerant and nontolerant mice. (1990) (17)
Lack of Transfer of Morphine Tolerance by Administration of Rat Cerebral Homogenates∗ (1968) (17)
Maintenance of acute morphine tolerance in mice by selective blockage of kappa opioid receptors with norbinaltorphimine. (1992) (17)
Electrophilic N-benzylnaltrindoles as delta opioid receptor-selective antagonists. (1995) (16)
Relative involvement of supraspinal and spinal mu opioid receptors in morphine dependence in mice. (1993) (16)
New gas chromatographic method for estimation of norepinephrine and dopamine in brain. (1972) (16)
Enhancement of superconducting transition temperature due to antiferromagnetic spin fluctuations in iron pnictides LaFe(As1-xPx)(O1-yFy): 31 P-NMR studies (2014) (16)
Effect of prolyl-leucyl-glycinamide and alpha-melanocyte-stimulating hormone on levorphanol-induced analgesia, tolerance and dependence. (1984) (16)
Difference between μ-receptors in the guinea pig ileum and the mouse vas deferens (1983) (16)
Sites of action of naloxone in precipitating withdrawal jumping in morphine-dependent mice: investigations by the ED50 value and CNS content of naloxone. (1993) (16)
Pharmacological profiles of beta-funaltrexamine (beta-FNA) and beta-chlornaltrexamine (beta-CNA) on the mouse vas deferens preparation. (1982) (16)
Two Fermi surface states and two $T_{\rm c}$-rising mechanisms revealed by transport properties in $R$FeP$_{1-x}$As$_x$O$_{0.9}$F$_{0.1}$ ($R$=La, Pr and Nd) (2013) (15)
Relative involvement of receptor subtypes in opioid-induced inhibition of intestinal motility in mice. (1982) (15)
Studies on the transport of morphine into the cerebrospinal fluid of rabbits. (1972) (15)
Effects of morphine, nalorphine and pentobarbital alone and in combination on cerebral glycolytic substrates and cofactors of rats in vivo. (1972) (15)
In vivo binding of naloxone to opioid receptors in morphine-dependent mice (1983) (14)
Alkylation of opioid receptor subtypes by alpha-chlornaltrexamine produces concurrent irreversible agonistic and irreversible antagonistic activities. (1983) (14)
7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors. (1997) (14)
The toxicity and analgetic activity of some congeners of salicylamide. (1953) (14)
Opioid antagonist activity of naltrexone-derived bivalent ligands: importance of a properly oriented molecular scaffold to guide "address" recognition at kappa opioid receptors. (1996) (14)
β-funaltrexamine (β-FNA) and neural tumor response in mice (1985) (13)
7'-Substituted amino acid conjugates of naltrindole. Hydrophilic groups as determinants of selective antagonism of delta 1 opioid receptor-mediated antinociception in mice. (1995) (13)
Design of peptidomimetic .delta. opioid receptor antagonists using the message-address concept [Erratum to document cited in CA112(25):235659s] (1990) (13)
Differential antagonism by naltrindole-5'-isothiocyanate on [3H]DSLET and [3H]DPDPE binding to striatal slices of mice. (1993) (13)
Potential nonequilibrium analgetic receptor inactivators. Synthesis and biological activities of N-acylanileridines. (1971) (13)
Aspartic acid conjugates of 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1(3-aminophenyl)-2-(1-pyrrolidi nyl) ethyl]acetamide: kappa opioid receptor agonists with limited access to the central nervous system. (1996) (13)
Further evidence that a single dose of an opiate can increase dopamine receptor sensitivity in mice. (1987) (12)
The effect of morphine on the incorporation of 3H-leucine into retinal proteins and subsequent axonal transport in the optic system of rats. (1975) (12)
Effect of narcotics on the uptake of serotonin precursors by the rat brain. (1977) (12)
Microsomal spectral properties and narcotic N-demethylase activity in methadone-dependent rats. (1976) (12)
Dose-dependent effects of prolyl-leucyl-glycinamide on morphine-induced analgesia, tolerance and dependence. (1984) (12)
Opioid receptor binding characteristics of the non-equilibrium mu antagonist, beta-funaltrexamine (beta-FNA). (1985) (11)
Bimorphinans as Highly Selective, Potent K Opioid Receptor Antagonists. (1987) (11)
Naloxone produces protracted tolerance in mice treated with a single dose of morphine. (1990) (11)
Possible contribution of a glutathione conjugate to the long-duration action of beta-funaltrexamine. (1993) (11)
The mu, kappa and delta properties of various opioid agonists. (1986) (10)
Potential nonequilibrium analgetic receptor inactivators. Further pharmacologic studies of N-acylanileridines. (1974) (10)
Kinetics of microsomal metabolism and binding of enantiomerically related substrates. (1973) (10)
EFFECT OF CENTRAL DEPRESSANT AGENTS ON CEREBRAL GLUCOSE 6‐PHOSPHATE DEHYDRO‐GENASE ACTIVITY OF RATS * (1965) (10)
Studies on the transport of morphine out of the perfused cerebral ventricles of rabbits. (1972) (10)
Interactions of leucine enkephalin and narcotics with opioid receptors. (1981) (10)
Isolation of selective 3H-chlornaltrexamine-bound complexes, possible opioid receptor components in brains of mice. (1980) (10)
Effect of morphine on cerebral glycolytic intermediates and enzymes of rats in vitro. (1969) (9)
Enhanced affinity of opiate receptors for naloxone in striatal slices of morphine-dependent mice. (1977) (9)
Antagonism by chlornaltrexamine of some effects of delta 9-tetrahydrocannabinol in rats. (1981) (9)
Irreversible blockage of opioid receptor types by ester homologues of beta-funaltrexamine. (1986) (9)
The effect of chronic administration of caffeine on morphine-induced analgesia, tolerance and dependence in mice. (1986) (9)
Antagonism of morphine-induced behavioral suppression by opiate receptor alkylators (1982) (8)
Effects of caffeine and 8-phenyltheophylline on the actions of purines and opiates in the guinea-pig ileum. (1986) (8)
Thermoelectric Properties of LaFePO1-xFx and LaFeAsO1-xFx –Possibility of the Hidden Mass Enhancement of LaFeAsO1-xFx– (2011) (8)
Activities of morphinone and N-(cyclopropylmethyl)normorphinone at opioid receptors. (1984) (8)
Activity of N-methyl-alpha- and -beta-funaltrexamine at opioid receptors. (1986) (8)
Pharmacology of highly selective, non-peptide delta opioid receptor antagonists (1990) (8)
Comparison of naloxone‐induced platform vertical jumping in the assessment of physical dependence in morphine‐dependent mice (1978) (8)
Improved assays for the assessment of kappa- and delta-properties of opioid ligands. (1982) (8)
Accumulation of methadone by the choroid plexus in vitro (1975) (8)
Stereospecific accumulation of dihydromorphine and naltrexone by corpus striatal slices of morphine-dependent mice (1982) (8)
Long-acting agonist and antagonist activities of naltrexamine bivalent ligands in mice. (1990) (7)
Enhanced naloxone potency and the development of narcotic tolerance. (1979) (7)
The uptake of morphine by the choroid plexus and cerebral cortical slices of animals chronically treated with morphine. (1971) (7)
Binaltorphimine-related bivalent ligands and their .kappa. opioid receptor antagonist selectivity [Erratum to document cited in CA108(17):150771q] (1988) (7)
Characteristics of mu and delta opioid binding sites in striatal slices of morphine-tolerant and -dependent mice. (1991) (7)
Kappa-selective opiate antagonist nor-binaltorphimine improves outcome after traumatic spinal cord injury in rats. (1987) (7)
3-Hydroxy-17-aralkylmorphinans as potential opiate receptor-site-directed alkylating agents. (1977) (7)
Investigation of the structural requirements for the kappa-selective opioid receptor antagonist, 6 beta,6 beta'-[ethylenebis(oxyethyleneimino)]bis[17-(cyclopropylmethyl)- 4,5 alpha-epoxymorphinan-3,14-diol] (TENA). (1986) (7)
Studies on the receptors involved in the action of the various agents in the phenylbenzoquinone analgesic assay in mice (1970) (6)
Effects of beta-funaltrexamine (beta-FNA) on morphine dependence in rats and monkeys. (1986) (6)
Erratum: 6β-[N,N-Bis(2-chloro-ethyl)amino]-17-(cyclopropylmethyl)-4,5α-epoxy- 3,14-dihydroxymorphinan (chlornaltrexamine), a potent opioid receptor alkylating agent with ultralong narcotic antagonist activity (Journal of Medicinal Chemistry (1978) 21, (598)) (1978) (6)
Spinal Delta Opioid Receptor Subtype Activity of 6-monoacetylmorphine in Swiss Webster Mice (1997) (6)
Mediation of nitrous oxide analgesia in mice by spinal and supraspinal kappa-opioid receptors. (1990) (6)
Effect of methamphetamine on the development of acute morphine tolerance and dependence in mice. (1978) (6)
Opioid agonist and antagonist activities of monofunctional nitrogen mustard analogues of beta-chlornaltrexamine. (1987) (6)
A Single-dose Suppression Test in Morphine-dependent Mice 1 (1974) (5)
6β-(N,N-BIS(2-CHLOROETHYL)AMINO)-17-(CYCLOPROPYLMETHYL)-4,5α-EPOXY-3# ,14-DIHYDROXYMORPHINAN (CHLORANALTREXAMINE), A POTENT OPIOID RECEPTOR ALKYLATING AGENT WITH ULTRALONG NARCOTIC ANTAGONIST ACTIVITY (1978) (5)
The mixed antinociceptive agonist-antagonist activity of beta-endorphin(1-27) in mice. (1993) (5)
Nonequilibrium opioid antagonist activity of 6,14-dideoxynaltrexone derivatives. (1987) (5)
Inhibition of naloxone-precipitated withdrawal jumping by i.c.v. and i.t. administration of saline in morphine-dependent mice. (1993) (5)
DESIGN AND SYNTHESIS OF NALTREXONE-DERIVED AFFINITY LABELS WITH NONEQUILIBRIUM OPIOID AGONIST AND ANTAGONIST ACTIVITIES. EVIDENCE FOR THE EXISTENCE OF DIFFERENT μ RECEPTOR SUBTYPES IN DIFFERENT TISSUES (1985) (5)
Difference between mu-receptors in the guinea pig ileum and the mouse vas deferens. (1983) (5)
Irreversible binding of [3H]β-funaltremaxine to brain slices of morphine-tolerant and -dependent mice (1988) (4)
DIPPA: An opioid receptor affinity label that produces selective and long-lasting κ antagonism in mice (1994) (4)
Cross-cellular adaptation to methadone and meperidine in cerebral cortical slices from morphinized rats. (1962) (4)
Affinity labels as probes for opioid receptor types and subtypes. (1986) (4)
Differential antagonism of DSLET and DPDPE by novel delta opioid receptor antagonists (1990) (4)
Searching for key parameter for determining Tc in Fe-based superconductors: Study of P/As substitution in RFe(P,As)(O,F) [R=La and Nd] (2011) (4)
Synthesis and Biological Activity of Analogues of β-Chlornaltrexamine and β-Funaltrexamine at Opioid Receptors (1986) (4)
Additions and Corrections - 6β[N,N-Bis(2-chloroethyl)amino]-17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan(Chlornaltrexamine), a Potent Opioid Receptor Alkylating Agent with Ultralong Narcotic Antagonist Activity (1978) (4)
The lag period associated with the stimulation of cerebral glucose utilization and co2 formation by morphine in vitro (1967) (4)
Intermediary and Energy Metabolism (1971) (4)
NARCOTIC ANTAGONISTIC POTENCY OF BIVALENT LIGANDS WHICH CONTAIN β-NALTREXAMINE. EVIDENCE FOR SIMULTANEOUS OCCUPATION OF PROXIMAL RECOGNITION SITES (1982) (3)
Enhanced oxidation of alpha-glycerophosphate by mitochondria of thyroid-fed rats. (1959) (3)
Effect of 6-hydroxydopamine and 5,6-dihydroxytryptamine on the response of the coaxially stimulated guinea-pig ileum to morphine. (1976) (3)
Suppression of Superconductivity around x = 0.5-0.7 in LaFeP 1- x As x O 0.95 F 0.05 (2014) (3)
IMPORTANCE OF CARBON 6 CHIRALITY IN CONFERRING IRREVERSIBLE OPIOID ANTAGONISM TO NALTREXONE-DERIVED AFFINITY LABELS (1984) (3)
Effect of morphine on the fate of newly transported tryptophan and 5-hydroxytryptophan in brain of rats. (1978) (3)
Accumulation of etorphine by slices of cerebral cortex and corpus striatum of rats. (1976) (3)
Erratum: Design of peptidomimetic δ opioid receptor antagonists using the message-address concept (Journal of Medicinal Chemistry (1990) Volume 33 (1714)) (1990) (3)
Characterization of leucine and methionine enkephalin and their interaction with morphine on the guinea pig ileal longitudinal muscle. (1978) (3)
The use of mu opioid receptors in the mouse vas deferens for the study of opiate tolerance. (1989) (3)
Synthesis and delta-opioid receptor antagonist activity of a naltrindole analogue with a regioisomeric indole moiety. (1994) (3)
Interaction of [ D-Pen 2 , 0-PenS ] enkephalin and [ DAla 2 , Glu 4 ] deltorphin with-opioid receptor subtypes in vivo (2002) (3)
Change of Fermi surface states related with two different Tc -raising mechanisms in iron pnictide superconductors (2018) (2)
ACTIVITIES OF MORPHINONE AND N-(CYCLOPROPYLMETHYL)NORMORPHINONE AT OPIOID RECEPTORS (1985) (2)
A753 QUANTITATIVE ASSESSMENT OF THE ANTINOCICEPTIVE EFFECTS OF MIDAZOLAM, AMITRIPTYLINE AND CARBAMAZEPINE ALONE AND IN COMBINATION WITH MORPHINE IN MICE (1990) (2)
Morphine release and displacement by naloxone in vivo in morphine naive and withdrawn rats. (1980) (2)
6beta-[N,N-Bis(2-chloroethyl)amino]-17-(cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan(chlornaltrexamine) a potent opioid receptor alkylating agent with ultralong narcotic antagonist actitivty. (1978) (2)
Binding characteristics of the specific μ antagonist β-FNA, the fumaramate methyl ester derivative of naltrexone (1981) (2)
3-HYDROXY-17-ARALKYLMORPHINANS AS POTENTIAL OPIATE RECEPTOR-SITE-DIRECTED ALKYLATING AGENTS (1977) (2)
beta-Funaltrexamine (beta-FNA) and neural tumor response in mice. (1985) (2)
β-Funaltrexamine (β-FNA) and morphine dependence (1984) (2)
IV. The effects of morphine, other opoids and their derivatives on the metabolism of the cerebral cortex. (1968) (2)
Synthesis and biological activity of analogues of beta-chlornaltrexamine and beta-funaltrexamine at opioid receptors. (1986) (1)
Synthesis and activity profiles of bivalent [Leu5]enkephalin-α-oxymorphamine hybrid opioid receptor ligands (1988) (1)
STEREOCHEMICAL STUDIES ON MEDICINAL AGENTS. 23. SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-AMINO DERIVATIVES OF NALOXONE AND NALTREXONE (1977) (1)
Role of the spinal cord in the development of opiate tolerance and dependence. (1987) (1)
Pharmacology of multiple opioid delta receptors (1993) (1)
Investigation of the Structural Requirements for the K-Selective Opioid Receptor Antagonist, 6β,6β′-[Ethylenebis(oxyethyleneimino)]bis[17-(cyclopropylmethyl)-4,5-epoxymorphinan-3,14-diol] (TENA). (1986) (1)
THE INFLUENCE OF MORPHINE ON GLUCOSE UTILIZATION IN CEREBRAL PREPARATIONS OF RATS. (1964) (1)
7-Benzylidenenaltrexone (BNTX), a highly selective δ1 antagonist, the first clear evidence for δ receptor subtypes based on binding (1993) (1)
USE OF THE NOVEL OPIATE, β-FUNALTREXAMINE (β-FNA) IN THE ELUCIDATION OF RECEPTOR TYPES INVOLVED IN OPIATE-MEDIATED RESPIRATORY DEPRESSION (1981) (1)
STRUCTURE-ACTIVITY RELATIONSHIP STUDY OF AFFINITY LABELS THAT ARE SPECIFIC FOR μ OPIOID RECEPTORS (1981) (1)
STEREOSTRUCTURE-ACTIVITY RELATIONSHIP OF OPIOID AGONIST AND ANTAGONIST BIVALENT LIGANDS. EVIDENCE FOR BRIDGING BETWEEN VICINAL OPIOID RECEPTORS (1985) (1)
Single Crystal Growth of Nd-1111 Iron Pnictide Superconductors by High Pressure Synthesis (2014) (1)
DIFFERENT RECEPTOR SITES MEDIATE OPIOID AGONISM AND ANTAGONISM (1984) (1)
Irreversible binding of [3H]beta-funaltrexamine to brain slices of morphine-tolerant and -dependent mice. (1988) (1)
Opioid pharmacology a'la mode. (1992) (1)
Alkylation of Opioid Receptor Subtypes by α-Chlornaltrexamine Produces Concurrent irreversible Agonistic and irreversible Antagonistic Activities. Stereochemical Studies on Medicinal Agents. Part 27. (1983) (0)
POTENTIAL NONEQUILIBRIUM ANALGETIC RECEPTOR INACTIVATORS, FURTHER PHARMACOLOGIC STUDIES OF N-ACYLANILERIDINES (1975) (0)
β-FNA-insensitive, opioid peptide preferring receptors in the guinea pig ileum (GPI) (1985) (0)
Enhanced affinity of mu-opioid receptors in morphine-dependent mice. (1990) (0)
A NOVEL OPIOID RECEPTOR SITE DIRECTED ALKYLATING AGENT WITH IRREVERSIBLE NARCOTIC ANTAGONISTIC AND REVERSIBLE AGONISTIC ACTIVITIES (1980) (0)
Effects of naltriben (NTB) on the development and expression of chronic dependence on morphine (1993) (0)
Effect of morphine on the incorporation of tryptophan and hydroxytryptophan into serotonin in the rat brain (1976) (0)
Antiferromagnetic Spin Fluctuations Enhancing Superconducting Transition Temperature in LaFeAsO-Based High-Tc Superconductors (2014) (0)
Synthesis and Biological Activity of Analogues of β-Chlornaltrexamine and β-Funaltrexamine at Opioid Receptors. (1987) (0)
Effect of narcotic analgesics on the uptake of serotonin precursors into the brain of the rat (1975) (0)
9aBD-11 Effect of P/As substitution on electronic properties of LaFeP_ As_xO (2014) (0)
Highly selective nonpeptide delta-opioid receptor agonists related to naltrindole (1990) (0)
TRANSPORT AND BINDING IN VIVO OF 3H-NALOXONE IN BRAINS OF MORPHINE DEPENDENT AND WITHDRAWN MICE (1981) (0)
Correlation between Tc and Transport Properties in PrFeP₁₋xAs[x]O₀.₉F₀.₁ (Proceedings of International Workshop on Heavy Fermions : TOKIMEKI 2011) (2012) (0)
Alterations in morphine-induced analgesia and tolerance by various compounds. (1980) (0)
Irreversible Blockage of Opioid Receptor Types by Ester Homologues of β-Funaltrexamine. (1987) (0)
Neuropeptides and Morphine Tolerance (1982) (0)
20pPSB-25 Effect of elemental substitution on Fe and As site in AFe_2As_2 (2010) (0)
An ultra-long lasting narcotic antagonist, chlornaltrexamine: Effects in vitro and in vivo (1978) (0)
413 – THE RELATIONSHIP OF CENTRAL BIOGENIC AMINE SYSTEMS WITH MORPHINE ANALGESIA AND NALOXONE ANTAGONISM (1977) (0)
SYNTHESIS AND PHARMACOLOGIC CHARACTERIZATION OF AN ALKYLATING ANALOG CHLORNALTREXAMINE, OF NALTREXONE WITH ULTRALONG-LASTING NARCOTIC ANTAGONIST PROPERTIES (1979) (0)
Ultralong lasting single-dose tolerance to chloroxymorphamine (COA), an opioid receptor alkylating agonist (1979) (0)
Specificity of in vivo opiate antagonism by chlornaltrexamine (1980) (0)
Transport properties of LaFeP$_{1-x}$As$_{x}$O$_{1-y}$F$_{y}$: Evidence for two superconducting states (2014) (0)
Selectivity of opioid agonists and antagonists for the various opioid receptor types. (1985) (0)
Opioid Agonist and Antagonist Activities of Monofunctional Nitrogen Mustard Analogues (I) of β-Chlornaltrexamine. (1987) (0)
Activity of N-Methyl-α- and -β-funaltrexamine at Opioid Receptors. (1987) (0)
BIOCHEMISTRY OF DRUG DEPENDENCE x838 (1974) (0)
Potentiation by leucine enkephalin of narcotic effects in vitro and in vivo (1981) (0)
27aEC-5 Relation between superconductivity andantiferromagnetic order/fluctuation around x=0.5-0.7 in LaFeP_ As_xO_ F_y (2013) (0)
DIFFERENTIAL EFFECTS OF LEU- AND MET-ENKEPHALIN ON NARCOTIC-INDUCED ENHANCEMENT OF NALOXONE EFFICACY (1980) (0)
[Gas chromatographic analysis of central biogenic amines and its application. 1]. (1973) (0)
Presence of Two Electronic States in LaFeP 1-xAs xO0.95 F0.05 (2014) (0)
909 – CHLORNALTREXAMINE, A NEW, POTENT, ULTRA-LONG ACTING NARCOTIC ANTAGONIST (1978) (0)
Isolation of kappa opioid receptor with an aminoethyl-nor-binaltorphimine (AE-norBNI) affinity column. (1990) (0)
Presence of Two Electronic States in LaFeP 1x As x O 0 . 95 F 0 . 05 (2014) (0)
Angle-Resolved Photoemission Spectroscopy Study of NdFeAs(O,F) Single Crystal (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Akira E. Takemori?

Akira E. Takemori is affiliated with the following schools: